French Sarcoma Group
9
1
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
11%
1 trials in Phase 3/4
50%
3 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma
Role: collaborator
Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas
Role: collaborator
Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST)
Role: collaborator
Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Role: collaborator
Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy
Role: collaborator
Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
Role: collaborator
National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group
Role: collaborator
Clinico-biological Study/Characterization of Rhabdomyosarcoma in Adolescents and Young Adults, 15-25-year-old Patients
Role: collaborator
Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS)
Role: collaborator
All 9 trials loaded